FAU is part of a $3.8 million NIH-funded research team developing a new class of drugs to combat the deadliest malaria parasite, Plasmodium falciparum. The research targets the parasite through an entirely new mechanism, with the goal of overcoming rising drug resistance and advancing next-generation therapies against one of the world’s deadliest infectious diseases.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.